Zentek Ltd.

NASDAQ:ZTEK

Other Precious Metals

Basic Materials
$0.49 +25.56%

+$0.10 today

Market cap
$62.30M
Beta
0.47
P/E (TTM)
-9.6
EPS (TTM)
-$0.08
52W Low $0.37High $1.34

Volume 0.93M

Average 0.15M

ZTEK Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Zentek Ltd.NASDAQ: ZTEK

Research & Development · Q4 FY2025 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q4 FY2025 research & development of CA$501.36K rose 146.6% year over year, behind the +255.2% change in trailing-twelve-month research & development. Sequentially, it fell 32.6% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Research & development amounted to 995.7% of revenue in FY2025, up 942.4 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +146.6% toward the trailing-twelve-month pace of +255.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$501.36K-32.6% QoQ
Last fiscal yearMar 2026
CA$1.66M+256.0% YoY
LTMMar 2026
CA$1.65M+255.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+146.6%——
1 year+256.0%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
1.66M CAD
Year-over-year change
+256.0%
4-year CAGR
+1.8%

Research & Development vs competitors

How ZTEK compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +255.2% is the highest of 9, against a peer median of -8.9%.
  • Research & development amounts to 995.9% of revenue for ZTEK, versus a peer median of 66.3%.
ZTEK Competitors
Research & Development for ZTEK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$70.7M USD-6.3%+29.5%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M USD-38.5%-7.9%—
AMWLAmerican Well CorporationLTM Mar 2026$63.14M USD-22.5%-19.3%26.6%
HYPRHyperfine, Inc.LTM Mar 2026$16.26M USD-26.0%-14.7%106.1%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$15.22M CAD+22.5%+0.1%—
MBOTMicrobot Medical Inc.LTM Mar 2026$6.11M USD-11.4%-6.7%5814.3%
BYSIBeyondSpring Inc.LTM Mar 2026$4.59M USD+218.0%-44.4%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$4.56M CAD+1.7%-13.6%24.8%
ZTEKZentek Ltd.LTM Mar 2026CA$1.65M CAD+255.2%+0.2%995.9%
Peer median (excluding ZTEK) —-8.9%-10.7%66.3%

Competitors are the stored peer set for ZTEK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue339.67K72.86K29.82K872.5K166.48K
Cost of Revenue376.79K853.34K331.08K680.01K6.47M
Gross Profit(37.12K)(780.48K)(301.26K)192.49K(6.3M)
Gross Margin-10.9%-1071.3%-1010.4%22.1%-3785.5%
Research & Development1.54M1.65M1.78M465.65K1.66M
Selling, General & Admin9.56M10.99M8.95M8.01M2.87M
Operating Expenses12.53M13.87M11.68M9.79M4.56M
Depreciation & Amortization614.71K539.69K613.71K600.32K527.77K
EBITDA(31.02M)(13.75M)(11.08M)(9.35M)(10.33M)
EBITDA Margin-9131.2%-18878.5%-37170.3%-1071.4%-6204.7%
Operating Income(12.56M)(14.65M)(11.98M)(9.6M)(10.86M)
Operating Margin-3698.5%-20112.5%-40174.8%-1100.4%-6521.7%
Interest Income20.6K510.26K405.48K101.61K40.41K
Interest Expense63.78K120.62K107.37K91.32K289.98K
Other Income / Expenses(19.13M)238.68K174.74K(439.03K)1.06M
Income Before Tax(31.69M)(14.41M)(11.8M)(10.04M)(9.79M)
Pre-Tax Margin-9330.9%-19784.9%-39588.7%-1150.7%-5882.6%
Income Tax Expense00(99.78K)00
Net Income(31.69M)(14.41M)(11.7M)(10.04M)(9.79M)
Net Margin-9330.9%-19784.9%-39254.1%-1150.7%-5882.6%
EPS (Basic)(0.42)(0.14)(0.12)(0.10)(0.09)
EPS (Diluted)(0.42)(0.14)(0.12)(0.10)(0.09)
Weighted Avg Shares92.09M99.44M97.53M102.98M105.92M
Weighted Avg Shares (Diluted)92.09M99.44M100.5M102.98M105.92M

Zentek Ltd.

NASDAQ:ZTEK

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.